{"id":"NCT03234907","sponsor":"Takeda","briefTitle":"Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-03","primaryCompletion":"2020-08-14","completion":"2020-08-14","firstPosted":"2017-07-31","resultsPosted":"2022-09-21","lastUpdate":"2023-03-01"},"enrollment":215,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Vedolizumab IV","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Induction Phase: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Induction Phase: Vedolizumab 300 mg","type":"EXPERIMENTAL"},{"label":"Maintenance Phase: Induction Placebo to Placebo Q4W","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W","type":"EXPERIMENTAL"},{"label":"Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W","type":"EXPERIMENTAL"},{"label":"Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.","primaryOutcome":{"measure":"Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10","timeFrame":"Week 10","effectByArm":[{"arm":"Induction Phase: Placebo","deltaMin":24.3,"sd":null},{"arm":"Induction Phase: Vedolizumab 300 mg","deltaMin":19.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.347"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b603b4db2bf003ab4a32b?idFilter=%5B%22Vedolizumab-3034%22%5D"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":70},"commonTop":["Pyrexia","Protein urine present","Nasopharyngitis","Upper respiratory tract infection","Anaemia"]}}